| Katherine Malavenda, LPC, MED | |
|
310a Calle Guard, Ramey, Aguadilla, PR 00603 | |
| (252) 626-1316 | |
| Not Available |
| Full Name | Katherine Malavenda |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 310a Calle Guard, Aguadilla, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346662905 | NPI | - | NPPES |
| 12543005 | Other | PR | CAHQ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | 4011 (Puerto Rico) | Primary |
| 101YP2500X | Counselor - Professional | 304149 (North Carolina) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Katherine Malavenda, LPC, MED Po Box 5968, Pmb 364, San Antonio, PR 00690 Ph: (252) 626-1316 | Katherine Malavenda, LPC, MED 310a Calle Guard, Ramey, Aguadilla, PR 00603 Ph: (252) 626-1316 |
News Archive
Led by researchers in the Nossal Institute for Global Heath at the University of Melbourne, the project is analyzing the stories and collating key lessons about health systems' responses to the pandemic across a range of places and over different time periods.
Because critical care nurses are often among those caring for patients during their final days, the American Association of Critical-Care Nurses joins national, state and community organizations in support of the third annual National Healthcare Decisions Day on Friday, April 16, 2010.
A novel, intelligent theranostic agent for precise tumor diagnosis and therapy has been developed that remains as small molecules while circulating in the bloodstream, can then self-assemble into larger nanostructures in the tumor, and be activated by the tumor microenvironment for therapy guided by photoacoustic imaging.
Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.
› Verified 2 days ago
Laura J Elias, ASSS Counselor Medicare: Not Enrolled in Medicare Practice Location: Anrxo Hospital Buen Samaritano, Centro De Tratamiento Con Metadona De Aguadilla, Aguadilla, PR 00603 Phone: 787-891-2360 | |
Evelyn Perez, Counselor Medicare: Not Enrolled in Medicare Practice Location: Centro Salud Conductual De Aguadilla, Ave. Kennedy #15, Aguadilla, PR 00603 Phone: 787-840-2575 Fax: 787-840-8391 | |
Christian Omar Furseth, M.S. Counselor Medicare: Not Enrolled in Medicare Practice Location: Urb . Vista Verde Calle 9 # 552, Aguadilla, PR 00605 Phone: 787-391-0890 | |
Linezka Zoe Diaz Gonzalez, LIC. Counselor Medicare: Not Enrolled in Medicare Practice Location: Carr #2 Km 98.7 Inte. Carr 110 Professional Plaza, Aguadilla, PR 00603 Phone: 787-517-2024 | |
Gilberto Herrera, PHD, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: Urb. San Carlos Calle Los Angeles #7-a, Aguadilla, PR 00603 Phone: 787-642-5271 | |
Selysmarie Martinez Gonzalez, PSYD Counselor Medicare: Medicare Enrolled Practice Location: Buen Samaritano Medical & Professional Plaza, Suite #5 Primer Piso Ave. Severiano Cuevas #18, Aguadilla, PR 00603 Phone: 787-560-6237 |